Torbjörn Bjerke appointed as CEO of Karolinska Development
(Thomson Reuters ONE) -
STOCKHOLM - January 14 2011, - Karolinska Development announces that Torbjörn
Bjerke will take up his position as CEO of Karolinska Development today.
Torbjörn Bjerke was formerly the President and CEO of Orexo AB, a position he
held from 2007. Previous positions include President and CEO of Biolipox AB and
Director of Pharmacology at AstraZeneca. He has also served as Executive Vice
President of R&D at ALK-Abello. Torbjörn Bjerke serves on the board of directors
of NeuroSearch AS and Paris based DBV Technologies.
"With his solid background as a commercial leader, Torbjörn Bjerke has the right
profile for the role as CEO for Karolinska Development. He has vast experience
from leading and developing early research-based companies as well as a listed
pharmaceutical company. Torbjörn has more than 20 years of experience in the
pharmaceutical industry and brings an extensive global network. He has a proven
track record in creating collaborations with world leading pharmaceutical
companies which will be of great value to us, our shareholders and our portfolio
companies", says Hans Wigzell, Chairman of Karolinska Development.
"I look forward to my new role as CEO of Karolinska Development, and to lead the
company to further success ", says Torbjörn Bjerke.
Torbjörn Bjerke succeeds Conny Bogentoft who played a central role in forming
Karolinska Development and has led the company since its inception in 2003.
With his vast experience in product development Conny Bogentoft will maintain an
active role in the company going forward.
For further information, please contact:
Hans Wigzell, Chairman of the board, Karolinska Development
Phone: +46 (0) 705 76 05 39, e-mail: hans.wigzell(at)ki.se
Torbjörn Bjerke, CEO, Karolinska Development
Phone: +46 (0) 727 44 41 23, e-mail: torbjorn.bjerke(at)karolinskadevelopment.com
TO THE EDITORS
About Karolinska Development
Karolinska Development manages one of the largest portfolios of life science
companies in Europe. Since its inception in 2003, Karolinska Development has
built a diversified portfolio of highly innovative life science companies.
Among the company's projects, 12 candidate drugs are undergoing clinical
development. www.karolinskadevelopment.com
Press release as PDF:
http://hugin.info/143071/R/1479794/415411.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Karolinska Development AB (publ) via Thomson Reuters ONE
[HUG#1479794]
Unternehmensinformation / Kurzprofil:
Datum: 14.01.2011 - 13:00 Uhr
Sprache: Deutsch
News-ID 50462
Anzahl Zeichen: 3197
contact information:
Town:
Solna
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 218 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Torbjörn Bjerke appointed as CEO of Karolinska Development"
steht unter der journalistisch-redaktionellen Verantwortung von
Karolinska Development AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
